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NEW POTENTIAL DIAGNOSTIC METHODS FOR IDENTIFYING
ANTICOAGULANT RODENTICIDE POISONING IN DOGS AND OTHER
NONTARGET ANIMALS
MICHAEL E. MOUNT, Department of Clinical Pathology, School of Veterinary Medicine, University of
California, Davis, California 95616.

Analytical methods for anticoagulants are complex and encumbered with highly sophisticated
instrumentation for determination of anticoagulant concentrations. This greatly limits the application
of anticoagulant measurement in biological samples as a diagnostic criteria to determine anticoagulant
rodenticide poisoning. In the field of veterinary medicine, clinical laboratory measurements of the
coagulation status in viable patients have been used historically as the means to make a diagnosis of
anticoagulant poisoning. Nontarget animals (companion animals, e.g., dogs and cats; livestock; or wildlife), which are found dead in the context of an anticoagulant application area, are a tremendous diagnostic challenge in spite of postmortem evidence of a hemorrhagic diathesis common to death from such
poisons. The recent understanding in the veterinary field (Mount and Feldman 1983, Mount et al. 1986)
of the short versus long-acting anticoagulants has created a diagnostic dilemma in relation of vitamin
Id therapy. It is therefore evident that analytical assays which possess high specificity, sensitivity,
and economic feasibility are needed to better clarify these issues.
Assays which possess those features are immunoassays. These have been applied to hormones and
steroids which are found at very low concentrations in biological fluids. They have also found application in drug monitoring and drugs-of-abuse identification in the medical field. The goal of this paper
is to give an understanding as to how immunoassays are developed and how applied to anticoagulants. The
development of such systems is timely and costly, but, once established, the cost per assay is minimal
and their applicability is adaptable to most laboratory settings. The enzyme-linked immunosorbent assay
(ELISA) is the immunoassay to be discussed. Using this system, assays can be run within an 8-hour day
and sensitivity is in the ng/mL range, which is parts per billion (ppb) of biological material.
The primary goal in developing an immunoassay is to produce antibodies in a living animal which
recognizes the substance of interest. When people are vaccinated with an infectious agent to protect
them from a specific disease, they are injected with proteins from a bacteria or virus. These materials
are antigenic, allowing their bodies' immune systems to be activated so as to process these foreign proteins, resulting in clones of lymphocytes which produce antibodies capable of recognizing these newly
introduced foreign proteins. Proteins are large molecular weight complexes (greater than ~ 40,000
g/mole). Steroids, therapeutic drugs, as well as anticoagulants, are low molecular weight compounds
(less than ~ 1000 g/mole) and are not antigenic. However, if these low molecular compounds are covalently coupled to proteins, they are made antigenic since antibodies produced against the coupled proteins
will recognize these low molecular compounds when present in a solution uncoupled to protein. Thus
these low molecular weight compounds can be defined as haptens; that is, by themselves these compounds
will induce antibody production. But, when coupled to proteins, antibodies are produced which recognize
the low molecular weight compounds when present in a solution containing the antibodies.
In order to produce antibodies against anticoagulants, which can be referred to as haptens, they
must be coupled to protein. Therefore, the first objective in the development of an immunoassay is to
covalently couple the anticoagulant to a protein. To do this, the anticoagulant (hapten) must have
chemical groups allowing for direct coupling to protein or allowing for attachment of a chemical bridge
which introduces a functional group allowing for covalent linkage to protein. This is summarized in
Figure 1. The resulting product is referred to as the immunogen and used to vaccinate rabbits. The

Figure 1. Basic steps required to convert a small
molecular weight compound (Hapten) into an antigenic derivative. The bridge represents a chemical unit which is capable of covalently binding to
the hapten so that the free end of the bridge contains a functional group which is able to covalently link to protein. Thus the HAPTEN is
functionalized by linkage with the BRIDGE allowing
for covalent binding with the PROTEIN. The protein-bound hapten is now antigenic.
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site of coupling is important in order to maintain high specificity of antibodies to the anticoagulant
of interest. Figure 2 demonstrates the two basic chemical structures of anticoagulants used in the field

Figure 2. All coumarin anticoagulants have the 4-hydroxy-coumarin nucleus
and all indandione anticoagulants have the indandione nucleus. The "R"
groups differ between the differing anticoagulants.
today. The --R group is the portion of the molecule which differentiates one coumarin (or indandione)
from the other. Thus the goal of our work has been to couple via the coumarin or indandione nucleus
thus exposing the --R group for antibody recognition.
Antibodies raised in rabbits following several months of immunogen vaccinations, are collected and
applied to the ELISA. A competitive ELISA has been developed for diphacinone and is outlined in Figure 3.

Figure 3. The competitive enzyme-linked
immunosorbent assay (ELISA) is illustrated.
1) Antibody specific for the anticoagulant is
adsorbed on to a solid support of a microtiter
plate. 2) Samples, standards, and control
reagents are added which occupy antibody
binding sites depending on the amount of anticoagulant in those samples. 3) The enzymeconjugate of anticoagulant covalently bound to
enzyme is added and more or less binds to the
remaining available antibody binding sites
depending on the amount of anticoagulant in
Step 2. 4) Substrate is added which is converted to a colored product dependent on the
amount of enzyme present. Thus an accurate
measure of the amount of anticoagulant and
specificity for an anticoagulant can be
determined.

The anticoagulant is coupled to the enzyme used in the assay. Antibody is a adsorbed onto a solid
surface (Step 1). Samples which may or may not contain the anticoagulant (the hapten) and analytical
standard concentrations of anticoagulant which are added to the solid surface will result in the "hapten"
occupying the available antibody binding sites (Step 2). Thus when the anticoagulant-coupled-to-enzyme
is added, more or less will occupy the antibody binding sites, depending upon how much anticoagulant was
present in the sample or standard (Step 3). Following this, the substrate is added (Step 4) and allowed
to develop, producing a color which can be measured with a spectrophotometer. The result is that a
standard curve is generated which allows for accurate determination of the anticoagulant (hapten) in the
biological sample.
Currently, diphacinone is readily detected in sera of dogs exposed to the anticoagulant diphacinone.
Chlorophacinone, which is identical to diphacinone except for one chlorine on the --R group, does crossreact with the antibody, but it requires approximately 10 times the concentration of chlorophacinone to
give the same effect as diphacinone. Sensitivity of the assay is 1 ppb. Since this compound is a longacting anticoagulant, dogs or cats presented to clinicians with a coagulopathy syndrome and responsive
to vitamin K1, can now easily be positively identified as poisoned with diphacinone. This allows clinicians to be aware of potential relapse of clinical signs if taken off of vitamin K 1 therapy too early.
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Currently a coupling method has been developed allowing for covalent linkage of the coumarin
nucleus to protein. Warfarin, brodifacoum, and bromadiolone are soon to be tested for antibody production.
In conclusion, the application of ELISA to anticoagulant analysis offers tremendous advantages over
conventional approaches. The diphacinone ELISA allows quick, sensitive analysis of sera and urines of
animals thought exposed to diphacinone. Once identified, therapeutic recommendations can be assuredly
made. The recent successful coupling of warfarin to protein opens the way to couple all coumarin anticoagulants with anticipation of being able to raise antibodies which are highly specific for each individual coumarin anticoagulant. With antibody in hand, ELISA development would follow, leading to rapid
identification of the coumarin anticoagulant responsible for poisoning. Technological developments are
currently available to perform rapid qualitative assays within 5 minutes using specially designed field
kits. Such a kit for anticoagulants (once developed) would offer a revolutionary change in anticoagulant analysis and provide tremendous advantages to the veterinarian as well as to researchers and commercial operators to perform field monitoring.
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